Since multiple conditions can mimic components of PAH, the clinician should think about the patient’s total clinical condition before diagnosing and categorizing it. Proper evaluation and etiologic definition are crucial to providing the appropriate therapy and prognosis.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
Interest in right-sided heart failure is on the upswing, but no formal statement has considered all major topics relevant to this syndrome. A new document from the AHA changes that.
While the incidence of CTEPH is low, diagnosis is important by a specialized multidisciplinary program that can provide a surgical cure.